KQ
Therapeutic Areas
CASI Pharmaceuticals Pipeline
| Drug | Indication | Phase |
|---|---|---|
| CID-103 (IV) | Antibody-Mediated Rejection (AMR) in Organ Transplant | Phase 1/2 |
| CID-103 (IV/SC) | Autoimmune Diseases (e.g., Immune Thrombocytopenia) | Preclinical |
| CID-103 (SC) | AMR / Autoimmune Diseases | Formulation Development |
| EVOMELA® | Multiple Myeloma (Conditioning) | Marketed |
| FOLOTYN® | Peripheral T-Cell Lymphoma | Marketed |
Leadership Team at CASI Pharmaceuticals
DC
David Cory
Chief Executive Officer
AZ
Alex Zukiwski
Chief Medical Officer
JC
Junping Chen
Chief Medical Officer, China
LZ
Larry Zhang
Senior Vice President
IC
Ingrid Choong
Head of Corporate Development
JG
Jim Goldschmidt
Chief Business Officer
HH
Hai Huang
CCO and GM (China)
CW
Chunhua Wang
Chief Operating Officer (China)
WG
Wei Gao
General Counsel
JH
James Huang
Non-Executive Chairman of the Board